Absci Corporation (ABSI)
NASDAQ: ABSI · Real-Time Price · USD
2.740
-0.070 (-2.49%)
At close: Feb 27, 2026, 4:00 PM EST
2.720
-0.020 (-0.74%)
After-hours: Feb 27, 2026, 7:39 PM EST
Absci Employees
As of December 31, 2024, Absci had 157 total employees, including 156 full-time and 1 part-time employees. The number of employees increased by 1 or 0.64% compared to the previous year.
Employees
157
Change (1Y)
1
Growth (1Y)
0.64%
Revenue / Employee
$17,930
Profits / Employee
-$729,962
Market Cap
412.02M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 157 | 1 | 0.64% |
| Dec 31, 2023 | 156 | -37 | -19.17% |
| Dec 31, 2022 | 193 | -19 | -8.96% |
| Dec 31, 2021 | 212 | 110 | 107.84% |
| Dec 31, 2020 | 102 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| REGENXBIO | 353 |
| Century Therapeutics | 150 |
| Enanta Pharmaceuticals | 120 |
| Niagen Bioscience | 104 |
| Verastem | 78 |
| PepGen | 57 |
| Anavex Life Sciences | 34 |
| DiaMedica Therapeutics | 28 |
ABSI News
- 4 days ago - Absci to Report Business Updates and Fourth Quarter and Full Year 2025 Financial and Operating Results on March 24, 2026 - GlobeNewsWire
- 11 days ago - Absci to Participate in Upcoming Investor Conferences - GlobeNewsWire
- 6 weeks ago - Absci Corporation (ABSI) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript - Seeking Alpha
- 2 months ago - Absci to Participate in the 44th Annual J.P. Morgan Healthcare Conference - GlobeNewsWire
- 2 months ago - Absci Corporation (ABSI) Discusses ABS-201 Program and Clinical Approach for Androgenetic Alopecia Transcript - Seeking Alpha
- 2 months ago - Absci Reports New Human Ex Vivo Data Demonstrating That ABS-201™ Stimulates Hair Growth and Regenerates Stem Cell Niche to Potentially Reverse Follicle Miniaturization - GlobeNewsWire
- 2 months ago - Absci and U.S. Soccer Legend Landon Donovan Partner to Champion the Patient Voice in Hair Loss Research - GlobeNewsWire
- 3 months ago - Absci Announces First Participants Dosed in Phase 1/2a HEADLINE™ Trial of AI-Designed Antibody ABS-201™ for Androgenetic Alopecia - GlobeNewsWire